Podcasts about Gene therapy

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're navigating through a myriad of transformative advancements reshaping the industry. From artificial intelligence-driven research breakthroughs to strategic acquisitions in emerging therapeutic areas, these developments are setting new benchmarks in drug discovery and patient care. **Strategic Acquisitions and Expansions:** Samsung Biologics' recent proposal to acquire Swiss CDMO Polypeptide for $1.8 billion marks a significant expansion into peptide production, underscoring the growing therapeutic importance of peptides. Their specificity and efficacy make them particularly appealing for metabolic disorders such as obesity. This acquisition reflects a strategic move to capture emerging market opportunities as demand for innovative metabolic treatments rises. Eli Lilly's bold $2.8 billion acquisition of Atai-Beckley highlights the pharmaceutical industry's shifting focus towards psychedelics. As mental health disorders like depression and PTSD become more prominent, psychedelics hold great promise for new therapeutic approaches. This acquisition may pave the way for further research and acceptance of psychedelics within mainstream medicine, offering new hope for patients. Another notable development is Tempus' acquisition of Personalisis for $1.5 billion. This move strengthens Tempus' cancer treatment portfolio by leveraging genomics-driven insights, emphasizing precision medicine's critical role in oncology. **AI Integration and Technological Innovation:** Bristol Myers Squibb is doubling down on AI integration by expanding its collaboration with Nvidia to build what promises to be the most powerful AI supercomputer dedicated to life sciences. This development is pivotal as it signifies a deeper commitment to harnessing computational power in R&D. By accelerating drug discovery and optimizing clinical trial processes, AI stands to revolutionize how treatments are developed and tailored to individual patients. Overall, these developments indicate a dynamic phase characterized by technological innovation and strategic collaborations. The integration of AI into drug development processes stands out as a transformative force, promising enhanced efficiency and efficacy in bringing new treatments to market. **Regulatory Milestones and Clinical Trials:** In regulatory news, Takeda's Qdenga has achieved a milestone by becoming India's first approved dengue vaccine. This approval is crucial in addressing neglected tropical diseases, with significant implications for public health in regions where dengue is prevalent. By reducing dengue fever incidence, this vaccine could play a vital role in improving health outcomes in many tropical countries. Promising results have emerged from clinical trials across various therapeutic areas. 4D Molecular Therapeutics reported an 87% reduction in treatment burden for wet AMD using their gene therapy candidate 4D-150 in Phase 2b trials—demonstrating potential as a transformative approach with reduced intervention frequency. Latigo Biotherapeutics' Nav1.8 inhibitor LTG-001 outperformed Vicodin in Phase 2 trials for acute pain, offering a non-opioid alternative amidst the opioid crisis. Meanwhile, Regenxbio's five-year data on surabgene lomparvovec shows sustained efficacy in wet AMD and diabetic retinopathy—underscoring its potential as a long-term treatment option. **Financial Performance and IPO Activity:** Financially, Abbott exceeded expectations with strong sales from their device and diagnostic divisions, prompting an upward revision of their full-year profit forecast. This reflects sustained demand for innovative diagnostic solutions and medical devices—highlighting Abbott's strategic market positioning. The IPO landscape remains active with companies like Nuvox Therapeutics seeking to raise funds for advancing oxygen therapeutics targeting hypoxia-related diseases—showcasing renewed investor interest and confidence within biotech innovation. Latigo Biotherapeutics is preparing for an IPO to advance its pipeline, demonstrating a strategic response to the opioid crisis. By developing alternatives that minimize addiction risks while providing effective relief, Latigo underscores the industry's commitment to safer pain management solutions. Turning to clinical trials, Scribe Therapeutics plans a $96 million IPO to advance its CRISPR-based lipid-lowering therapies, marking significant interest in genetic solutions for cardiovascular diseases like hyperlipidemia. The precision offered by CRISPR technology could revolutionize treatment options for conditions contributing significantly to cardiovascular health burdens. **Geopolitical Influences:** Geopolitical factors are also influencing market dynamics, particularly in the UK biotech sector where IPO plans are being shaped by global uncertainties despite robust venture capital backing. This situation underscores the complex interplay between regional economic conditions and global investment trends in biotech innovation. As these trends continue unfolding across the industry landscape—from AI-driven research advancements to strategic acquisitions—the potential impact on patient care paradigms remains profound. These developments not only promise new possibilities within drug development but also influence broader healthcare delivery models aimed at improving patient outcomes globally.Support the show

The first person has been treated with a highly anticipated new gene therapy that aims to turn back the clock on ageing cells. The trial is aimed at retinal cells, with the hope that encouraging them to behave as if they were young again could improve sight in the affected patients. If it proves to be safe, it could open the door to a whole raft of therapies based on the emerging field of cellular rejuvenation. To understand more about this cutting edge research, Madeleine Finlay hears from science editor Ian Sample and from Paul Knoepfler, professor of cell biology and human anatomy at the university of California, Davis.. Help support our independent journalism at theguardian.com/sciencepod

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the latest advancements shaping the future of drug discovery and patient care. Veradermics is making significant strides with its oral minoxidil formulation aimed at addressing female pattern hair loss. The mid-stage clinical trial results have analysts optimistic about Veradermics' potential to capture a significant portion of this underserved market. The oral form of minoxidil, traditionally used in topical Rogaine products, offers a novel delivery method that could enhance patient adherence and improve outcomes, marking an innovative leap in dermatological treatments. Johnson & Johnson is navigating the expiration of Stelara's patent protection with resilience, as Tremfya steps up to fill the revenue gap. With quarterly sales exceeding $2 billion, Tremfya underscores the critical role of strategic lifecycle management and robust product pipelines in weathering patent cliffs. This success highlights the necessity for pharmaceutical companies to sustain growth through a well-rounded portfolio that can absorb such impacts. In oncology, Celcuity has achieved a pivotal milestone with FDA approval for its small molecule inhibitor targeting breast cancer. This therapy promises blockbuster potential and could become a new standard-of-care, expanding treatment options for patients. The approval reflects ongoing innovation in oncology, where small molecules continue to play an essential role alongside biologics in advancing cancer therapies. AI-driven drug discovery is gaining traction as Insilico Medicine partners with CDMO Bora in a potentially $2.5 billion deal. This collaboration underscores AI's transformative potential in accelerating drug discovery and development processes. By leveraging artificial intelligence, Insilico aims to identify new drug candidates more efficiently, expediting their journey from bench to bedside. Kelun-Biotech is marking significant progress with its SAC-TMT program targeting non-small cell lung cancer (NSCLC), filling gaps left by Merck's phase 3 efforts. This development is crucial for providing more tailored therapeutic options in oncology, illustrating how advancements in drug development are driving forward personalized medicine. Roche continues its exploration of Alzheimer's disease treatments with a multifaceted approach that includes both amyloid and tau proteins as targets. While its phase 3 amyloid program is prominent, Roche's interest in tau protein highlights the complexity of tackling neurological disorders and the need for diverse therapeutic strategies. Meanwhile, Biogen remains steadfast in defending its anti-tau Alzheimer's candidate following mixed phase 2 results that showed slowed cognitive decline. Despite stock volatility, this endeavor illustrates the high-stakes nature of Alzheimer's research as companies pursue novel approaches to this challenging disease. Regulatory landscapes are also shifting as Johnson & Johnson halts development of an eye disease gene therapy after disappointing phase 2b results. This move reflects the inherent risks involved in gene therapy and underscores the necessity for thorough evaluation at each clinical stage. Medtronic's recall of its Harmony delivery catheter system due to potential detachment risks serves as a reminder of the paramount importance of safety and quality control in medical device manufacturing. Such recalls impact patient safety and emphasize regulatory vigilance over device reliability. In summary, these innovations demonstrate the dynamic nature of the pharma and biotech industries where cutting-edge science drives progress. Integrating AI into drug discovery, managing product lifecycles post-patent expiry, advancing personalized medicine, and maintaining regulatory diligence collectively shape a landscape focused on improving patient outcomes worldwide. Turning to recent scientific developments: Eli Lilly's presentation at AAIC 2026 on their anti-amyloid Alzheimer's drug Kisunla explores maintenance therapy possibilities once amyloid levels fall below a threshold. This potential shift could signify a paradigm change by extending therapeutic benefits and possibly improving long-term outcomes for patients with Alzheimer's. Biogen's advances with its anti-tau Alzheimer's therapy partnered with Ionis Pharmaceuticals further validate the tau hypothesis. The promising mid-stage data on their antisense drug Diranersen opens opportunities for other companies like Denali Therapeutics to explore similar avenues for treating neurodegenerative diseases. The industry is also witnessing a resurgence in biotech IPOs during 2026's first half, recovering from a sluggish 2025. This surge signals investor confidence in biotechnological innovation while providing capital for advancing research pipelines. Financial activities within the sector are robust as Attovia Therapeutics files for an IPO to fund its competitive pipeline against Sanofi's Dupixent. Meanwhile, Advancell's $315 million Series D funding supports advancing prostate cancer candidates into Phase 3 trials, backed by big pharma confidence in radiotherapy's potential. Lastly, regulatory transparency improves as the FDA resumes releasing drug rejection letters after a temporary pause—a move likely to influence future submissions significantly by offering clearer guidance on regulatory expectations. These developments collectively highlight how scientific innovation and strategic maneuvers transform pharmaceutical landscapes, promising profound impacts on patient care through advanced therapies and novel treatments worldwide. As these trends unfold, they reflect an industry increasingly reliant on technological integration and collaborations to drive future growth and innovation.Support the show

Gene therapy has changed what is possible for people living with sickle cell disease. New treatments have shown that the condition can be successfully treated. But the therapy is costly and available to only a small number of patients. Millions of people around the world still rely on early diagnosis and preventative medicines, with access to basic care remaining a challenge in many places, including sub-Saharan Africa, which has almost 80% of global sickle cell cases. Are we closer to gene therapy for sickle cell disease being accessible?We speak to Dr Natasha Archer, director of the Sickle Cell Program at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, US; Dr Alexis Thompson, paediatric haematologist at the Children's Hospital of Philadelphia and a professor of paediatrics at the University of Pennsylvania, US; Dr Leon Tshilolo, professor of paediatrics and haematology at the University of Mbuji-Mayi, DR Congo and Prof Baba Inusa, consultant paediatrician in the School of Life Course & Population Sciences at King's College London, UK(Photo: Cell lines are prepared in a laboratory in Maryland, US. Credit: Brendan Smialowski/Getty Images)Presenter: Daniel Rosney Producer: Matt Toulson Researcher: Evie Yabsley Sound engineer: Cameron Ward Production co-ordinator: Phoebe Lomas and Liam Morrey Editor: Tom Bigwood

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative updates and strategic shifts within the industry, reflecting both remarkable progress and inherent challenges. Sanofi's recent achievement marks a significant milestone in oncology with the FDA approval of Sarclisa Escena (isatuximab) as the first on-body injector for multiple myeloma treatment. This monoclonal antibody, targeting CD38, offers a novel subcutaneous delivery method, simplifying administration and potentially enhancing patient compliance by reducing the need for frequent clinic visits. This aligns with the industry's ongoing shift towards patient-friendly drug delivery systems, emphasizing convenience without compromising efficacy. In another promising development, GSK and Hansoh Pharmaceutical have reported positive results from their Phase 3 trial evaluating risvutatug rezetecan for small cell lung cancer. This antibody-drug conjugate, targeting B7-H3, has shown potential when combined with chemotherapy to extend patient survival. Given the aggressive nature of small cell lung cancer and limited treatment options, these findings underscore the potential of targeted therapies to improve clinical outcomes significantly. Forte Biosciences' FB102 also takes a spotlight in clinical advancements. In its Phase 1b trial for vitiligo, FB102 demonstrated a 45.8% placebo-adjusted benefit. This monoclonal antibody works by modulating immune responses through the IL-15 pathway via CD122, offering new hope for patients with this challenging autoimmune condition. On the regulatory front, ARPA-H's commitment of up to $160 million towards developing personalized genetic medicines for rare diseases is noteworthy. This investment is set to accelerate innovations in gene therapy and personalized medicine platforms. Such advancements promise to revolutionize pediatric care and extend beyond by tailoring treatments to individual genetic profiles, enhancing efficacy while minimizing adverse effects. Strategic collaborations continue to reshape the industry landscape. Rani Therapeutics' partnership with PegBio aims at advancing oral delivery systems for obesity and metabolic diseases. Similarly, Simcere Pharmaceutical's collaboration with Schrödinger leverages AI-driven drug discovery efforts. These alliances highlight an increased reliance on computational platforms to streamline therapeutic development processes. From a financial perspective, Mesoblast Limited reports substantial revenue from its cell therapy product Ryoncil, signaling strong commercial viability for cell-based treatments targeting rare diseases. Additionally, Cue Biopharma's successful $50 million fundraising underscores investor confidence in advancing therapies for immunological disorders. However, not all news is positive. Roche has decided to halt two programs targeting Huntington's disease due to inadequate efficacy and safety concerns. This decision reflects the complexities involved in developing effective treatments for neurological disorders—a field fraught with scientific challenges yet rich with potential rewards. In market dynamics, McKinsey's report advocates for a structural redesign of biopharmaceutical R&D to fully leverage AI's capabilities. This recommendation resonates with current industry trends focusing on strategic innovation to maximize efficiency and discovery potential. The FDA's third rejection of Hengrui Pharma and Elevar Therapeutics' combination therapy for liver cancer underscores the rigorous scrutiny such treatments face despite their promise in addressing complex cancers. In contrast, BioNTech's preparation to launch its HER2 antibody-drug conjugate (ADC) signifies its strategic pivot back towards oncology after mRNA vaccine successes. Bayer's decision to sell a minority stake in its contraceptives business demonstrates how companies are strategically realigning portfolios to focus on core areas while securing funding for innovation. This move reflects broader trends within pharma as companies navigate financial landscapes to support long-term research goals. Amid these developments, regulatory environments continue evolving. NICE's stance against future Lumakras reimbursement in the UK highlights ongoing challenges in balancing cost-effectiveness with access to innovative therapies. Meanwhile, ARPA-H's significant funding allocation signals robust governmental support for advancing precision medicine within genetic therapies. In conclusion, today's updates reveal an industry characterized by a relentless pursuit of innovation amidst complex regulatory landscapes. As companies navigate these dynamics through strategic collaborations and scientific breakthroughs, their efforts hold promise for enhancing patient care across diverse therapeutic areas globally. Stay tuned as we continue to track these exciting developments shaping the future of pharmaceuticals and biotechnology. Thank you for tuning into Pharma Daily—your go-to source for up-to-date insights from the world of pharmaceuticals and biotechnology.Support the show

The case of baby KJ Muldoon, an infant born with a lethal genetic metabolic disorder, demonstrates the potential to compress years of therapeutic development into months using an in vivo base editing approach. Jeff Coller, director of the Johns Hopkins RNA Innovation Center, wrote about the case in a New York Times op-ed, arguing that CRISPR-based base editors—delivered via lipid nanoparticles as mRNA molecular surgery payloads—could be generalized to thousands of monogenic disorders. He further explains that realizing this promise will be constrained less by scientific limitations than by regulatory, manufacturing, and reimbursement challenges. Coller also outlines what it will take to make bespoke therapies economically and operationally viable, and argues that failure to scale this approach would reflect not a failure of science, but of imagination.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping our industry, starting with a significant regulatory milestone. Vera Therapeutics recently achieved FDA accelerated approval for Trutakna, a groundbreaking treatment for IgA nephropathy. This approval not only provides new hope for patients suffering from this chronic kidney disease but also highlights the innovative approach targeting APRIL and BAFF pathways, crucial in immune system regulation. The drug's accelerated approval is particularly noteworthy as it offers earlier access to promising therapies while further trials solidify its benefits. This positions Vera Therapeutics against industry giants like Novartis and Otsuka in nephrology therapeutics, highlighting the competitive landscape within this sector. The FDA's expedited pathways are increasingly facilitating quicker access to life-saving drugs, aligning regulatory processes with scientific advancements to address unmet medical needs. The spotlight on fusion proteins in tackling autoimmune and renal disorders could signal a broader trend in therapeutic development. In parallel, AstraZeneca has made waves by entering into a major licensing agreement with Sino Biopharmaceutical for their COPD candidate TQC3721. This $1.9 billion deal, with a $200 million upfront payment, exemplifies how global collaborations are becoming pivotal in expanding market reach. By focusing on respiratory diseases, AstraZeneca is strategically positioning itself to enhance treatment options for COPD patients worldwide, reflecting an industry-wide movement towards leveraging regional expertise in drug commercialization. Meanwhile, Evonik's $100 million investment in an Indiana API manufacturing plant marks a strategic effort to bolster domestic production capacities post-pandemic. This investment underscores the rising demand for Contract Development and Manufacturing Organization (CDMO) services, emphasizing supply chain resilience—an increasingly critical factor as biotech firms seek reliable production partners. On the clinical trial front, Satellos Bioscience has reported promising Phase 1 data for SAT-3247, its Duchenne muscular dystrophy candidate. This AAK1 inhibitor demonstrates potential in promoting muscle regeneration, a development that could significantly alter treatment paradigms for this progressive neuromuscular disorder. If further trials confirm these findings, it could revolutionize therapeutic approaches for rare diseases. Financially, Leo Cancer Care's recent $65 million Series D funding is set to advance its upright radiotherapy treatment system. Such innovations aim to improve precision and outcomes in cancer therapy, at the intersection of technology and patient care. Similarly, MeiraGTx's securing of up to $400 million from Oberland Capital underlines ongoing confidence in gene therapies targeting rare ophthalmological conditions. Strategic maneuvers continue to reshape industry landscapes with mergers like that of Caidya and Simbec-Orion forming a global CRO platform aimed at enhancing research capabilities across oncology and rare diseases. Such consolidations reflect broader trends towards operational efficiencies and scaling research capabilities globally. Amidst these developments, quality control remains paramount as evidenced by Amgen's recall of its heart failure drug due to quality concerns. Such challenges reiterate the importance of stringent quality assurance throughout production processes in safeguarding patient safety. Vertex's acquisition of Crinetics for $10 billion marks another strategic expansion into "white space blockbuster opportunities," illustrating how M&A activity is driving companies to bolster pipelines and capitalize on emerging scientific advancements. These developments collectively underscore the dynamic nature of the pharmaceutical and biotech industries as they navigate complex regulatory landscapes, financial recalibrations, and scientific breakthroughs. As companies strive towards more effective and accessible treatments across various therapeutic areas, their ability to adapt to these challenges remains crucial in shaping the future of healthcare delivery. Thank you for tuning into Pharma Daily. Stay informed with us as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

What if the future of medicine is not just treating disease once it appears, but correcting it at its source?In this episode of The Wellness Algorithm, Anshu Bahanda is joined by Dr Patrick Sewell, founder of Triple Helix Science, to understand gene therapy in simple, human terms. Together, they unpack a cutting edge and often controversial area of medicine, exploring how gene therapy works and why it is being studied for cancer, Alzheimer's, muscular dystrophy, addiction, depression and even longevity. This conversation looks at what gene therapy could mean for the future of prevention, precision medicine and even the way we understand disease itself.Leave a review

New gene therapies have changed what may be possible for some sickle cell patients. But providers say the path to treatment remains long, expensive and difficult to access.

AI and Generative Biology: Authoring Life, Redesigning Healthcare, and Building Guardrails: Physician and molecular biologist Dr. Adrian Woolfson, co-founder of Genyro, a biotechnology company specializing in synthetic genome design and construction, and author of “On the Future of Species: Authoring Life by Means of Artificial Biological Intelligence,” discusses the convergence of AI with synthetic/generative biology that could make biology programmable and enable genome design and construction beyond traditional gene editing. Woolfson argues that the technology is morally neutral but is arriving rapidly and requires public awareness, governance, and guardrails due to risks, including misuse by authoritarian regimes and biological warfare. He discusses evolution's trade-offs and why he favors limiting human applications to curing disease and extending healthy longevity, while opposing germline modification; he explains germline vs somatic editing and cites the flawed, unethical case of a Chinese scientist attempting inherited HIV resistance. They examine sickle cell disease cures costing $2–$3 million, scalability issues, and trade-offs like malaria protection, and highlight non-medical benefits such as engineered crops, biomaterials, desalination, and DNA-based information storage.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

Purespring Therapeutics is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Haseeb Ahmad, CEO of Purespring, who discusses transforming the treatment of kidney disease, an area of enormous unmet need, with more than 840 million people worldwide living with chronic kidney disease. Indeed, Purespring's lead programme is the podocyte-targeted gene therapy PS-002, which is for IgA nephropathy (or IgAN). The conversation also touches upon the evolution of the gene therapy landscape more generally, and where next with this type of innovation in the nephrology space. You can listen to episode 267 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we dive into some significant advancements reshaping the industry. Starting with a breakthrough in gene therapy, researchers have announced promising results from a Phase 1 clinical trial targeting a rare genetic disorder known as Leber congenital amaurosis. This disorder causes childhood blindness due to mutations in the RPE65 gene. The investigational therapy involves delivering a functional copy of the gene directly to retinal cells using an adeno-associated virus vector, showing substantial improvements in visual function for participants. This development not only brings hope to those affected by this condition but also underscores the growing potential of gene editing technologies in addressing previously untreatable genetic disorders. While these are early-stage results, they contribute to a growing body of evidence that gene therapy can effectively target and treat specific genetic abnormalities. In regulatory news, the FDA has granted accelerated approval to a novel small-molecule drug for the treatment of metastatic triple-negative breast cancer. This drug acts as an inhibitor of a specific kinase involved in cancer cell proliferation and has shown statistically significant improvements in progression-free survival compared to existing therapies. Triple-negative breast cancer is particularly challenging to treat due to its aggressive nature and lack of hormone receptors that typically guide treatment decisions. The approval marks a critical step forward, offering a new therapeutic option for patients with limited alternatives. As this treatment enters broader clinical use, ongoing post-marketing studies will be crucial in confirming its long-term efficacy and safety profile. Meanwhile, in Europe, the European Medicines Agency has recommended approval for an innovative biologic targeting severe asthma. This monoclonal antibody works by selectively binding to and inhibiting a cytokine involved in the inflammatory cascade that triggers asthma symptoms. Clinical trials demonstrated significant reductions in asthma exacerbations and improved lung function among patients who were inadequately controlled on standard therapies. With asthma affecting millions globally, advancements like these are essential for improving quality of life and reducing healthcare burdens associated with poorly controlled respiratory conditions. Turning our attention to Alzheimer's research, scientists have reported encouraging findings from a late-phase clinical trial evaluating a novel anti-amyloid antibody. The trial results indicate that the drug successfully slowed cognitive decline in patients with early-stage Alzheimer's disease. This aligns with the amyloid hypothesis, which suggests that amyloid-beta plaque accumulation in the brain is a driving factor in Alzheimer's pathology. Although previous attempts targeting amyloid have met with limited success, this latest trial offers renewed optimism for potentially modifying disease progression rather than just managing symptoms. On the topic of industry trends, there's been a notable increase in strategic partnerships between major pharmaceutical companies and emerging biotech firms specializing in mRNA technology. Following the unprecedented success of mRNA vaccines during the COVID-19 pandemic, there is considerable interest in exploring mRNA platforms for treating a wide range of diseases beyond infectious ones, including cancer and rare genetic disorders. These collaborations aim to leverage complementary strengths: established companies bring regulatory expertise and manufacturing capabilities, while biotech firms offer innovative technologies and nimble research approaches. The synergy could accelerate the development pipeline and bring transformative therapies to market more rapidly. Lastly, we explore an intriguing development in personalized medicine. A team of researchers has unveiled an AI-driven platform designed to optimize drug regimens tailored specifically to individual patients' genetic profiles. By integrating genomic data with machine learning algorithms, this tool can predict patient-specific responses to various treatments and suggest optimal dosing strategies. This approach holds promise not only for enhancing therapeutic efficacy but also for minimizing adverse effects by accounting for individual variability in drug metabolism and response. As we continue to witness rapid advancements across various sectors of pharma and biotech, it's clear that innovation is at the forefront of transforming patient care and addressing some of the most challenging medical conditions of our time. Thank you for joining us today on Pharma Daily. Stay tuned for more updates on groundbreaking research and pivotal industry developments shaping healthcare's future landscape.Support the show

Guys, check out b-Vibe's 360 Plug — the male equivalent of the rabbit. It's a remote-controlled vibrator with 360° rotation, a smooth silicone body, and simultaneous prostate and perianal pleasure. Grab yours at bvibe.com and use code TABOO25 for 25% off!Erectile dysfunction affects tens of millions of men in the U.S., yet stays wrapped in silence and shame. In this episode, I bust the biggest ED myth — that it's a permanent, unfixable part of aging — and walk through the full range of treatment options available today. I cover penile implants, vacuum erection devices, testosterone replacement therapy, and FDA-approved medications like Viagra and Cialis, then move into natural approaches: therapy, lifestyle changes, key nutrients, and sex toys that keep intimacy alive during treatment. I close with a look at emerging treatments on the horizon — shockwave therapy, stem cells, PRP, and gene therapy — and a clear call to action: talk to your doctor, because ED is treatable and no one has to navigate it alone.In This Episode:00:00 — bvibe 360 Plug (code TABOO25)00:50 — Podcast Intro / Welcome to Taboo to Truth01:10 — Welcome Back + ED Stats01:55 — What This Episode Will Cover02:15 — Myth-Busting: ED Is NOT a Permanent Part of Aging03:00 — Treatment #1: Penile Implants04:05 — Treatment #2: Vacuum Erection Devices (Pumps)05:00 — Treatment #3: Testosterone Replacement Therapy (TRT)05:50 — Treatment #4: FDA-Approved Medications (Viagra, Cialis, Levitra, Stendra)06:35 — Natural Approaches: Counseling & Sex Therapy07:35 — Lifestyle Changes & Key Nutrients (Citrulline, Vitamin D/E, Zinc)08:20 — Sex Toys: Staying Intimate During Treatment09:10 — The Future of ED Treatment (Shockwave, Stem Cells, PRP, Gene Therapy)10:05 — Fastest Way to Fix ED + Key Takeaway11:00 — Outro: Subscribe + Hotter, Wiser, Wilder CourseWant a deeper look? Watch the full episode on YouTube for a more visual experience of today's discussion. This episode is best enjoyed on video—don't miss out!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of remarkable advancements and strategic maneuvers that are shaping the future of drug development and patient care. Starting with Roche's breakthrough in oncology, their small molecule inhibitor, Divarasib, has shown promising results in a Phase 3 trial for patients with KRAS G12C-mutated non-small cell lung cancer. This trial demonstrated superior efficacy over competitors like Amgen's Lumakras and Bristol-Myers Squibb's Krazati. Historically, KRAS mutations have been difficult to target, but Divarasib's success underscores the potential of precision medicine in oncology. These findings could lead to more effective treatment options for NSCLC patients, showcasing how targeted therapies are revolutionizing cancer treatment by focusing on specific genetic mutations. In regulatory news, Vertex Pharmaceuticals has made significant strides with Casgevy (exagamglogene autotemcel), a gene therapy that now includes pediatric patients with sickle cell disease and transfusion-dependent beta thalassemia in its FDA-approved label. This marks a pivotal moment for gene therapy applications in blood disorders. Utilizing CRISPR technology, Vertex offers potentially curative solutions for debilitating conditions, signaling a new era where genetic disorders can be addressed at their root cause. Similarly, Novartis has gained European Commission approval for Itvisma to treat 5q spinal muscular atrophy in patients aged two years and older, further cementing gene therapies' role in mainstream medical practice. Strategic partnerships remain essential in driving innovation. Takeda's collaboration with Insilico Medicine on AI-driven drug discovery is a case in point. The $600 million partnership highlights the growing reliance on AI and machine learning to expedite therapeutic development processes. Platforms like Pharma.AI are being leveraged to identify novel drug candidates more efficiently. Additionally, AstraZeneca's alliance with CSPC Pharmaceutical Group to develop siRNA-based therapies for kidney diseases reflects the burgeoning interest in RNA therapeutics as these technologies open new avenues to address complex diseases. On the financial front, BridgeBio's ability to attract $1 billion in convertible preferred equity from Sixth Street and Healthcare Royalty underscores investor confidence in rare disease therapeutics. This funding will bolster its pipeline targeting cardiovascular and rare conditions, emphasizing the profitable potential found within niche markets of the pharmaceutical landscape. Manufacturing is also seeing expansion as Lonza deepens its partnership with an unnamed U.S. drugmaker to enhance biologics programs. Anticipated investments reaching into multi-billion Swiss Francs underscore the critical importance of robust manufacturing infrastructure to meet growing demands for biologics and antibody-drug conjugates. Clinical trials continue to yield promising results. Can-Fite Biopharma's Phase 2a trial for Namodenoson in treating advanced pancreatic ductal adenocarcinoma has shown promising survival data when combined with therapies targeting Wnt/β-catenin signaling pathways. At the same time, Otsuka's Phase 3 data for Voyxact (sibeprenlimab-szsi) demonstrated improved kidney function in patients with immunoglobulin A nephropathy, bolstering traditional FDA approval pathways. On the acquisitions front, GNI Group's acquisition of Ayumi Pharmaceutical for approximately JPY 44.8 billion highlights strategic moves to enhance global biopharma operations focusing on pain management solutions. Yet not all news is positive; Sanofi's Genzyme Ireland unit received an FDA warning letter regarding manufacturing violations related to Altuviiio production, pointing to ongoing regulatory challenges within production practices. Moving on to geopolitical considerations, recent congressional letters to major pharmaceutical CEOs have raised concerns about clinical trials conducted within China due to national security concerns. This tension illustrates the delicate balance between leveraging China's economic potential and safeguarding US interests—a critical issue as international collaborations continue to expand. Meanwhile, AstraZeneca's ongoing collaborations with CSPC Pharmaceutical Group further signify strategic bets on China's capabilities despite geopolitical tensions. Their joint efforts focus on kidney disease treatments while adding to existing agreements addressing obesity and chronic diseases. The FDA remains pivotal as key decisions anticipated this quarter could significantly influence investment strategies and research priorities. This includes revisiting applications previously delayed or rejected—decisions that could reshape industry dynamics. In conclusion, this dynamic landscape is marked by significant scientific breakthroughs and complex global interactions guiding pharmaceutical and biotech sectors toward a transformative era. Gene therapy advancements underscore progress in personalized medicine while geopolitical factors continue influencing strategic industry decisions. As regulatory bodies evolve their approaches alongside increasingly international partnerships, these developments collectively herald profound implications for drug development and patient care globally.Support the show

The cell and gene therapy industry faces massive hurdles—cost, scalability, and the need for highly skilled operators have historically limited the reach of these transformative treatments. advanced therapy medicinal products manufacturing innovation is urgently needed to overcome these challenges and unlock broader global access.Farlan Veraitch, founder and Chief Scientific Officer at Ori Biotech, is leading the way in reimagining manufacturing platforms using automation, modularity, and digital transformation. His vision is redefining how cell and gene therapies are produced—from research labs to point-of-care hospital settings.What's inside:The use and adaptation of the paper pull tab sterile connection system—miniaturized and multiplexed—to ensure reliable material transfer in the manufacturing process (06:36)How modular and stackable system design supports scale-up and scale-out, increasing manufacturing capacity and flexibility (09:17)Full digitization of the Ori platform, including setting up digital twins, integrating sample prep automation, and capturing data for QA/QC in real time (10:11)Deskilling bioprocess operations, reducing the need for highly trained cell culture staff, and enabling broader use in both centralized facilities and hospitals (14:02)The logistical benefits of separating material prep (like buffer and virus formulation) from the manufacturing site to streamline point-of-care applications (15:39)Farlan's vision for an accessible, profitable, globally distributed manufacturing platform to support new treatment pipelines (17:14)Driving down cost and improving scalability as key challenges to unlocking the potential of cell and gene therapies (18:49)Strategic insight:The cell and gene therapy field needs to lower manufacturing costs and increase production. Focused, practical approaches are required to make these life-changing therapies more efficient, scalable, and accessible to more patients around the world.Listen for practical perspectives on automation, digital tools, manufacturing infrastructure, and the future possibilities for decentralized, scalable cell and gene therapy production.Connect with Farlan Veraitch:LinkedIn: www.linkedin.com/in/farlan-singh-veraitch-a677112Email: farlan.veraitch@oribiotech.comOri Biotech: www.oribiotech.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

What if the simple act of opening an incubator could undermine the consistency of your cell therapy manufacturing process? Unlike traditional biologics, the moment cells leave their incubator, subtle shifts in temperature, CO₂, and pH can spiral into mission-critical variability, jeopardizing everything from product yield to therapeutic potency.This episode features Farlan Veraitch, founder and Chief Scientific Officer of Ori Biotech. Trained at UCL's Department of Biochemical Engineering, Farlan blends a bioprocess engineer's mindset with hands-on experience scaling monoclonal antibodies, before pioneering the first-ever automation platform for embryonic stem cell culture. His drive for eliminating variability and designing systems that scale seamlessly from bench to bedside has informed ORI's approach to modular cell therapy manufacturing.What you'll hear in this episode:The importance of controlling pH, temperature, and shear forces in cell therapy manufacturing (00:36)Lessons learned from scaling monoclonal antibody production and its impact on biotech business models (05:23)The unique sources of variability in primary and stem cells, and why automation is essential (11:16)Strategies to minimize human-induced variability in sensitive cell cultures (12:59)How exposure to ambient oxygen and CO₂ during manual processing affects cell viability (14:13)The logic behind Ori Biotech's modular design to solve environmental control issues (19:04)Strategic insight:As cell and gene therapies push boundaries, manufacturing must keep pace with exponentially tighter requirements. Farlan's journey highlights a universal lesson for scientists and engineers: process control is not just a technicality, but a necessity for reproducible, scalable, and commercially viable therapies.If you're grappling with process variability or looking for fresh strategies in cell and gene therapy development, this episode offers an inside view from a scientist who's worked at the intersection of bioprocess, automation, and commercial translation.Connect with Farlan Veraitch:LinkedIn: www.linkedin.com/in/farlan-singh-veraitch-a677112Email: farlan.veraitch@oribiotech.comOri Biotech: www.oribiotech.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

In episode 81 of Going anti-Viral, Dr Steven Deeks joins host Dr Michael Saag to discuss recent research demonstrating the promise of a single shot in a functional cure of HIV. Dr Deeks is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and is a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. He is an internationally recognized expert on HIV pathogenesis and treatment and is the contact principal investigator of the Delaney AIDS Research Enterprise (DARE), an NIH-funded international collaboratory aimed at developing therapeutic interventions to cure HIV infection. Dr Deeks and Dr Saag discuss why a cure for HIV is needed given the effectiveness antiretroviral therapy. Dr Deeks then outlines areas of research demonstrating promise for single-shot functional cures: vector immunotherapy, the use of Chimeric Antigen Receptor (CAR) T cells, and stem cell approaches. Finally, Dr Deeks provides insights into future prospects in HIV cure research including his perspective on the funding and drug development landscape. 0:00 – Introduction 1:21 – The need for a cure beyond antiretroviral therapy5:37 – Overview of 1-shot cure research  12:40 – The promise of vector immunotherapy18:52 – Overview of the use of CAR-T cells 25:01 – The role of C-C chemokine receptor type 5 (CCR5) and stem cell approaches26:36 – Prospects for the future of HIV cure research __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of this dynamic industry. Replimune has made headlines with the resubmission of its oncolytic virus-based immunotherapy, RP1, to the U.S. Food and Drug Administration for treating advanced melanoma. The FDA's acceptance after two prior rejections is significant, suggesting a shifting regulatory landscape that could favor innovative cancer therapies like oncolytic viruses. These therapies represent a novel approach to engage the immune system in targeting tumors, and if RP1 gains approval, it may open doors for similar treatments, potentially offering new hope for melanoma patients. On the regulatory side, Amgen has encountered challenges with Tavneos after losing European Union endorsement due to data integrity issues. This serves as a stark reminder of the critical importance of maintaining stringent data management throughout drug development. With an FDA hearing on the horizon, the implications are far-reaching, emphasizing increased scrutiny from regulatory bodies worldwide. This scenario could lead to more rigorous guidelines governing data practices in the future. The European Commission's approval of Henlius' Hetronifly as a first-line treatment for squamous non-small cell lung cancer marks a milestone in cancer immunotherapy. This approval highlights the ongoing efforts to improve patient outcomes through innovative PD-1 inhibitor-based combination therapies, showcasing progress in the fight against one of the most challenging forms of cancer. Epicrispr Biotechnologies brings promising news from its phase 1/2 trial of EPI-321, a gene therapy for facioscapulohumeral muscular dystrophy. The trial's success in enhancing muscle function through epigenetic silencing underscores significant advancements in gene therapy applications for neurological disorders. Similarly, Abbisko Therapeutics' phase 2 trial reports a 90% objective response rate using FGFR2/3 and PD-L1 inhibitors for gastric cancer, demonstrating the potential of targeted small molecule therapies in oncology. In financial developments, Definium Therapeutics and Ligachem Biosciences have made substantial funding strides to bolster their drug development pipelines. Definium's $805 million raise aims to advance psychiatric and neurological treatments, while Ligachem's funding will enhance its antibody-drug conjugate platforms. These investments reflect strong investor confidence in next-generation therapeutic platforms and underscore innovative financing strategies crucial for sustaining research and development efforts. Bayer's recent legal victory at the Supreme Court overturning a $1.25 million verdict related to its Roundup product is another focal point. This ruling not only positively impacts Bayer's financial standing but also highlights the complexities surrounding product liability cases within pharmaceuticals and agrochemicals. Strategically, Moderna has unveiled an ambitious R&D roadmap aiming for break-even by 2028 with over seven new products on the horizon. By focusing on mRNA vaccines for oncology and rare diseases, Moderna continues to leverage its technology beyond COVID-19 applications, potentially transforming treatment paradigms across various therapeutic areas. Shifting focus to industry trends, Sanofi finds itself under investigation by the European Commission for antitrust violations linked to its flu vaccine marketing practices. This situation underscores growing scrutiny over competitive practices within the pharmaceutical sector and could influence regulatory compliance strategies across global markets. In technological advancements, Eli Lilly is employing artificial intelligence to raise awareness about Alzheimer's disease through creative engagements like a European radio show road trip. These initiatives reflect an industry-wide shift towards technology-driven marketing strategies aimed at personalizing patient interactions. Lastly, Merck KGaA's $11 billion acquisition of Bio-Techne exemplifies a strategic move to enhance capabilities in immune cell therapy production. This deal underscores the growing importance of manufacturing innovations in bringing advanced therapies to market and highlights strategic collaborations increasingly seen across the sector. The landscape is further defined by significant scientific breakthroughs such as Revolution Medicines' development of a second RAS blocker, showing improved chemotherapy responses in pancreatic cancer patients. These advancements underscore the need for continued investment in targeted therapeutics research as they promise better patient outcomes and highlight ongoing innovation within oncology. As these developments unfold, they reflect an industry poised for transformation amid evolving scientific, regulatory, and market dynamics aimed at improving patient care globally. With these insights into current trends and future directions, it's clear that the pharmaceutical and biotech sectors are navigating a period rich with potential for groundbreaking advancements that will shape healthcare outcomes worldwide.Support the show

Send us Fan MailFor decades, scientists have searched for better cancer drugs. But what if the biggest challenge isn't discovering the drug - it's getting it to the tumor? My guest today is developing programmable viruses designed to travel throughout the body, selectively amplify inside metastatic lesions, and transform tumors into factories for their own destruction.Dr. Eric Poma, Ph.D. is Chief Executive Officer of Calidi Biotherapeutics ( https://www.calidibio.com/ ), a biotechnology company developing targeted genetic medicines designed to deliver therapeutic payloads directly to tumors throughout the body.Dr. Poma brings more than three decades of experience across biotechnology, oncology drug development, business development, and capital markets. Prior to joining Calidi in 2025, he served as CEO of Molecular Templates, where he helped raise more than $250 million in equity financing and secured strategic partnerships with companies including Takeda, Vertex, and Bristol Myers Squibb.Earlier in his career, Dr. Poma held leadership roles at ImClone Systems during the rise of targeted cancer therapies, served as Vice President of Business Development at Innovive Pharmaceuticals, and worked as a healthcare and biotechnology analyst. He holds a Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill and an MBA from NYU's Stern School of Business.Today we will discuss one of the most difficult challenges in oncology - how to successfully deliver powerful therapies to metastatic tumors throughout the body - and how Calidi's RedTail platform aims to use engineered oncolytic viruses as targeted delivery vehicles capable of reaching cancer cells, modifying the tumor microenvironment, and potentially enabling a new generation of genetic medicines.#CancerResearch #Oncology #Immunotherapy #GeneTherapy #Biotechnology #CancerTreatment #PrecisionMedicine #OncolyticVirus #CancerScience #BiotechInnovation #MetastaticCancer #IL15 #VacciniaVirus #GeneticMedicine #SyntheticBiology #TumorMicroenvironment #FutureOfMedicine #DrugDelivery #Biopharma #EricPoma #CalidiBiotherapeutics #CancerBreakthrough #MedicalInnovation #LifeSciences #ProgressPotentialPossibilitiesSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting stories shaping the industry right now. Let's start with a groundbreaking advancement in gene therapy. Researchers have achieved a significant milestone by successfully using CRISPR technology to treat a rare genetic disorder in humans. This marks one of the first times that CRISPR has been applied directly to patients in such a way, offering hope for those suffering from conditions previously thought untreatable. This development is not just about treating one disorder; it opens up a world of possibilities for addressing various genetic diseases. By precisely editing genes at their source, scientists are paving the way for therapies that could revolutionize how we approach genetic disorders. Shifting gears to regulatory news, the FDA has granted accelerated approval to a new Alzheimer's drug that targets amyloid plaques in the brain. This drug, through its unique mechanism of action, aims to slow down cognitive decline in patients diagnosed with early-stage Alzheimer's disease. While there remains debate about the amyloid hypothesis itself, this approval signals a hopeful step forward in treating a condition that affects millions worldwide. As researchers continue to explore and understand Alzheimer's pathology, such approvals encourage further innovation and investment into neurodegenerative research. In clinical trial news, a biotech company has announced promising results from its Phase 3 trial of an mRNA-based vaccine for respiratory syncytial virus (RSV). The trial demonstrated high efficacy in preventing severe RSV infections among older adults, a population particularly vulnerable to this virus. These results not only underscore the versatility of mRNA technology but also highlight how quickly platforms developed during the COVID-19 pandemic can be adapted for other infectious diseases. This advancement suggests a future where rapid response to emerging viral threats becomes more feasible. Meanwhile, in the realm of oncology, there's been an exciting development with a novel immunotherapy showing potential in treating pancreatic cancer. This approach involves modifying patients' own immune cells to better recognize and attack cancer cells, a technique known as CAR-T cell therapy. Although traditionally successful in blood cancers, applying it to solid tumors like pancreatic cancer has been challenging due to their dense and protective tumor microenvironments. Early data indicate that this immunotherapy may penetrate these barriers more effectively, offering new hope for patients facing one of the deadliest forms of cancer. On a broader scale, the industry continues to see an increase in collaborative efforts between pharmaceutical giants and smaller biotech firms. These partnerships are essential for fostering innovation and speeding up drug development processes. By combining resources and expertise, companies can tackle complex health challenges more efficiently than ever before. Such collaborations also reflect an industry trend towards open innovation models that prioritize agility and shared knowledge over traditional competition. Finally, let's touch on an emerging trend that's capturing attention: personalized medicine's growing influence on drug development strategies. With advances in genomics and data analytics, pharmaceutical companies are increasingly tailoring therapies to individual patient profiles rather than adopting a one-size-fits-all approach. This shift not only improves treatment efficacy but also reduces the likelihood of adverse reactions, ultimately leading to better patient outcomes and more efficient healthcare systems. These stories illustrate an industry at the cutting edge of science and technology, driven by a relentless pursuit of new ways to improve human health. Each breakthrough not only represents progress but also carries profound implications for future research directions and therapeutic possibilities. That's all for today's edition of Pharma Daily. Stay tuned as we continue to bring you more updates on these exciting developments in pharmaceuticals and biotechnology. Thank you for listening, and we'll be back soon with more insights from this dynamic field.Support the show

Children's Health is one of a few pediatric centers nationwide authorized to administer Skysona gene therapy for boys with early, active cerebral adrenoleukodystrophy (cALD). Tune in to hear about clinical criteria and real-world impact. More on Skysona here.  Learn more about Dr. Aquino.  Learn more about Dr. Kayani. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a rapidly evolving landscape marked by significant scientific breakthroughs, regulatory shifts, and strategic business maneuvers. The pharmaceutical and biotech sectors are buzzing with renewed vigor, as evidenced by an impressive resurgence in mergers and acquisitions. A recent analysis by PwC reports that M&A activity has reached over $65 billion in deal value during the first quarter of 2026, marking the strongest quarter since 2020. This uptick underscores a robust confidence within the industry, with companies strategically leveraging these mergers to bolster their pipelines and explore new therapeutic territories. Eli Lilly's acquisition of non-opioid pain drugmaker 4E is a case in point, as it reflects a broader industry shift towards precision medicine and non-opioid pain management solutions—a response to growing concerns over opioid addiction. On the regulatory front, notable developments include Colorado's drug import plan receiving FDA approval. This marks a bold step in curbing drug costs across the U.S., although implementation challenges remain due to complex logistical and regulatory landscapes. Meanwhile, Novo Nordisk is expanding its global manufacturing footprint with a new plant in the Czech Republic for diabetes and obesity drugs, alongside a $29 million investment to upgrade its Chinese facility. This expansion aligns with Novo's strategic preparation to seek Chinese regulatory approval for its Wegovy pill, potentially transforming the obesity treatment landscape. In a move that could reshape vaccine development, Moderna is advancing its mRNA-based influenza vaccine candidate through regulatory channels. The FDA's favorable reviews ahead of an advisory committee meeting highlight the growing acceptance of mRNA technology beyond COVID-19 vaccines. This technology holds promise for transforming vaccine development across various infectious diseases. Precision oncology continues to grapple with translating scientific discoveries into practical applications that genuinely improve patient outcomes. The ASCO 2026 conference emphasized this critical transition from discovery to implementation as essential for advancing precision medicine. Turning to gene therapy, UniQure is preparing for a significant milestone—submitting an accelerated Biologics License Application for its Huntington's disease therapy. This follows a reversal by the FDA, which now considers UniQure's Phase 1/2 trial data sufficient for submission. Should this therapy gain approval, it would be groundbreaking as the first genetic medicine for Huntington's disease, setting a precedent for future gene therapies targeting other genetic disorders. In another strategic partnership, Jazz Pharmaceuticals has teamed up with AbCellera to develop T-cell-engaging antibodies for oncology indications, illustrating the potential financial rewards associated with innovative cancer therapies. This collaboration could yield up to $820 million per program and highlights how partnerships are crucial in expediting drug development timelines. These stories reflect broader industry trends emphasizing innovation and strategic partnerships while navigating complex regulatory landscapes. The focus on precision medicine and advanced biologics continues to drive scientific advancements, with companies like Vedana Therapeutics targeting unmet needs in neurology through novel therapeutic approaches. Meanwhile, international collaboration is gaining traction in regulatory processes. The newly launched transatlantic liaison program between the FDA and MHRA aims to accelerate drug approvals and foster innovation across borders—an initiative that underscores the importance of collaborative frameworks. However, not all news is optimistic. Be Biopharma's decision to terminate its hemophilia B cell therapy trial highlights the challenges companies face in competitive therapeutic areas. Despite previous optimism, similar withdrawals by Pfizer and BioMarin indicate the necessity for robust clinical data and clear market differentiation strategies. Furthermore, Merck's recent agreement with Protillion Technologies marks an increased focus on integrating artificial intelligence into drug discovery processes—a trend promising accelerated timelines and improved trial success rates. As these developments unfold, it's evident that the pharmaceutical and biotech sectors are at an intersection where scientific innovation meets strategic business decisions. The potential approval of UniQure's gene therapy could catalyze further advancements in genetic medicine—while M&A activities suggest an industry poised for transformative growth. For stakeholders—from researchers to executives—the ability to adapt to these dynamic changes will be crucial in shaping the future of drug development and patient care. In conclusion, these stories collectively paint a picture of an industry evolving through scientific breakthroughs while adapting through strategic business decisions. As new technologies integrate into this space alongside regulatory advancements in gene therapy, this period of transformation holds promising implications for addressing unmet medical needs and enhancing therapeutic outcomes globally.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape. Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for hereditary angioedema. This gene therapy utilizes CRISPR technology combined with antisense oligonucleotides, highlighting the transformative potential of genetic editing techniques. The success of this approach underscores CRISPR's promise in offering long-term solutions through single-dose treatments, setting a benchmark for future therapies targeting genetic disorders. Regulatory dynamics are also shifting, as evidenced by Germany's move to abandon its variable drug discount plans after major pharmaceutical companies like Boehringer Ingelheim and Eli Lilly withdrew investments. This decision highlights the ongoing complexities and challenges in drug pricing policies, which are vital for maintaining equitable access to medications while ensuring economic sustainability for pharmaceutical companies. On the manufacturing front, Recipharm is investing significantly to upgrade its U.S. production capabilities in response to rising demand for biologics. This trend reflects an industry-wide push towards expanding biologic drug manufacturing infrastructure, driven by biologics' potential for personalized medicine applications. Similarly, Eisai has secured a UK government grant to expand its Hatfield plant for monoclonal antibody production, while Johnson & Johnson is investing $1 billion to enhance Acuvue contact lens production. These expansions illustrate how major companies are bolstering manufacturing capabilities to support strategic growth and meet increasing product demand. Merck & Co.'s partnership with Protillion Biosciences, valued at $510 million, exemplifies the growing integration of AI/ML technology in drug discovery. This collaboration aims to leverage Protillion's Prot-map protein design platform to enhance data generation and accelerate biologics development, illustrating how artificial intelligence is streamlining drug discovery processes. In clinical trials, promising developments continue to emerge. Spyre Therapeutics reported that SPY002 met its Phase 2 primary endpoint in ulcerative colitis with anti-TL1A results, positioning it as a potential leader in autoimmune disease therapies. Edgewise Therapeutics also presented supportive Phase 2 data for EDG-7500, which targets hypertrophic cardiomyopathy, paving the way for Phase 3 trials. These advancements highlight the potential of small molecules and combination therapies in addressing complex diseases. Additionally, Alto Neuroscience's ALTO-207 has shown benefits for anhedonia in major depressive disorder patients through independent Phase 2 data. This underscores ongoing progress in treating neurological disorders using innovative combinations of established compounds like dopamine agonists and ondansetron. The landscape is further enriched by Moderna's expansion plans. Anticipating up to three new product launches between 2027 and 2028, Moderna is restructuring its operations under new leadership. This strategic realignment aims to streamline processes across commercial, manufacturing, and R&D divisions ahead of significant product launches. Regulatory collaboration is advancing, with the FDA and UK's Medicines and Healthcare products Regulatory Agency (MHRA) initiating a new liaison program. This initiative aims to harmonize regulatory responses across borders, potentially accelerating drug approvals.Support the show

In this episode of our pediatric neurology series, host Paul Wirkus, MD, FAAP and guest Josh Bonkowsky, MD explore the rapidly evolving field of gene therapy and its potential to transform the care of children with neurologic disorders. Our guest explains the science behind gene therapy, including how these treatments work to target the underlying causes of genetic disease.The conversation also examines emerging approaches to gene editing and the exciting possibilities these technologies hold for the future of pediatric medicine. Alongside the promise of these innovations, we discuss the challenges, ethical considerations, and unanswered questions that accompany this new era of precision medicine.Throughout the episode, our guest emphasizes the importance of helping patients and families understand complex treatment options so they can make informed decisions as the landscape of genetic diagnosis and therapy continues to evolve.Have a question? Email questions@vcurb.com. Listener questions will be answered in episode four. For more information about available credit, visit vCurb.com.ACCME Accreditation StatementThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Colorado Medical Society through the joint providership of Kansas Chapter, American Academy of Pediatrics and Utah Chapter, AAP.  Kansas Chapter, American Academy of Pediatrics is accredited by the Colorado Medical Society to provide continuing medical education for physicians. AMA Credit Designation StatementKansas Chapter, American Academy of Pediatrics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In this episode, we discuss the promising results of intravitreal gene therapy for neovascular AMD with 4D-150 with Dr. Arshad Khanani of Sierra Eye Associates and Clinical Professor of Ophthalmology at the University of Nevada Medical School, Reno.

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Dr. William Li: Eat to Beat Disease, Extend Longevity, and Hack Your Vascular Health Your body already has a built-in cancer defense system, and the foods you eat can rival prescription drugs at activating it. In this episode, you'll discover what 720,000 living centenarians reveal about longevity, why microplastics are reaching your brain through your nose, and how your blood vessels hold the real key to biological aging. -Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey sits down with Dr. William Li, an internationally renowned physician, scientist, and two-time New York Times bestselling author of "Eat to Beat Disease" and "Eat to Beat Your Diet." As President and Medical Director of the Angiogenesis Foundation, Dr. Li's groundbreaking research has led to the development of more than 40 new medical treatments impacting care for over 70 diseases including diabetes, heart disease, blindness, and obesity. His TED Talk, "Can We Eat to Starve Cancer?", has surpassed 11 million views, making him one of the most trusted voices at the intersection of functional medicine and food as medicine science. Together they dig into the biology of SuperAgers, the vascular markers that predict how long you'll live, and why flow-mediated dilation may be the most underrated biohacking measurement tool available today. Dave shares what happened after four separate gene therapies, including klotho and VEGF, and Dr. Li explains why your metabolism, mitochondria, and gut microbiome show up in the data on every centenarian ever studied. They also get into the microplastic crisis, the cribriform plate pathway that delivers airborne particles directly to your brain, and why your tongue is the first place your body quietly stores fat. You'll Learn: What centenarian research reveals about immune function, gut health, and vascular resilience Why 50% of food extracts matched or outperformed cancer drugs in head-to-head angiogenesis testing How microplastics travel through your nose directly to your central nervous system What flow-mediated dilation and pulse wave velocity tell you about your true biological age Why your hind-third tongue fat is an overlooked early warning sign for sleep apnea and metabolism problems What Dave's four gene therapies (klotho, VEGF, follistatin) actually did to his body How the vagus nerve connects gut health to brain optimization, stress resilience, and longevity Why genetics now accounts for roughly half of longevity outcomes, and what that means for the future of gene therapy How to use biohacking tools to compound your health the same way you compound financial returns Thank you to our sponsors! - Beyond Wonderland Conference | Oct 13 - 14, 2026. Get your ticket now at wonderlandconference.com. - Amp | If you're ready to make fitness fit into your life, go to amp.ai to check it out - Caldera + Lab | A small habit with big results. Go to CalderaLab.com/DAVE and use code DAVE for 20% off your first order. - Calroy | Go to Calroy.com/DAVE for exclusive discounts on Arterosil HP, Vascanox HP and all Calroy products. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights inhealth, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: William Li, Dr. William Li, Eat to Beat Disease, angiogenesis, food as medicine, centenarians, SuperAgers, longevity, anti-aging, biohacking, vascular health, flow-mediated dilation, pulse wave velocity, microplastics, cribriform plate, gene therapy, klotho, VEGF, follistatin, mitochondria, metabolism, gut health, vagus nerve, sleep apnea, functional medicine, human performance, brain optimization, cancer prevention, inflammation, immune system Resources: • Learn More About Dr. Li's Work At: https://drwilliamli.com • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Trailer 02:33 – William's Background 06:21 – Food vs. Cancer Drugs 14:09 – Gene Therapy 23:50 – Centenarian Research 27:41 – Stress & the Vagus Nerve 37:31 – Vascular Health 42:34 – Microplastics 53:19 – Novel Biomarkers See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A panel of clinical pharmacists meets to discuss the complex process of operationalizing cell and gene therapy at an academic medical center.

Friedreich's ataxia is a progressive, multisystem disease that robs people of coordination, independence, and often life itself. Until recently, there had been no approved therapies. In Friedreich's ataxia, a genetic mutation causes a deficiency in frataxin, a protein that plays an essential role within mitochondria and affects enzymes involved in energy production. Solid Biosciences is developing a gene therapy designed to restore frataxin where it is needed. Friedreich's Ataxia Research Alliance CEO Jennifer Farmer and Solid Biosciences chief medical officer Gabriel Brooks discuss the lived reality of Friedreich's ataxia, Solid Bioscience's next-generation gene therapy now in development to address the underlying cause of the disorder, and what genuine partnerships between patient organizations and industry look like when patient priorities drive trial design and development decisions.

Today's episode is a very special one. We are joined by Anna and her mother, Chelle, to discuss what it is like to live with Leber congenital amaurosis (or LCA) and to understand the patient experience of receiving retinal gene therapy with Luxturna, the first FDA approved gene therapy in medicine.  Subscribe to the podcast:  https://MayoClinicOphthalmology.podbean.com   Follow and reach out to us on X and IG: @mayocliniceye 

Gene therapy is changing how clinicians care for patients with rare and genetic diseases, with more therapies moving from research into clinical use. In this episode, Dr. Nirali Shah is joined by Dr. Christy Duncan and Dr. Sung‑Yun Pai to talk through recent progress in the field and what it actually takes to deliver these treatments at the patient level.The discussion draws on their experience in transplant and genetic disease, covering both scientific advances and the operational challenges that come with implementing gene therapy — especially in complex and resource‑intensive settings. Tune in for a conversation that covers:Recent developments in gene therapy, including in vivo approaches and newly approved treatmentsBarriers to broader use, including access, equity, and long-term monitoringWhat centers need to consider when building a gene therapy program, from workflows to team coordinationWhere things may be heading, including more individualized therapies and efforts to expand availabilityListen to the episode below or on your favorite app. Subscribe to ASTCT Talks and share this episode with your colleagues to keep the conversation going.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest news shaping the industry, from breakthroughs in cancer therapies to advancements in AI-driven drug discovery. Starting with regulatory updates, the potential appointment of Richard Pazdur, M.D., as the new FDA Commissioner is causing quite a stir. Following Marty Makary's resignation, Pazdur has emerged as a prominent candidate due to his extensive background in oncology drug regulation. Known for his commitment to accelerating cancer therapy approvals, his potential leadership could maintain or even amplify the focus on expediting innovative treatments for cancer patients. In a significant regulatory achievement, Beone Medicines celebrated the FDA's approval of Beqalzi, marking it as the first BCL-2 inhibitor approved for mantle cell lymphoma. This approval challenges AbbVie's Venclexta and underscores a growing trend towards targeted cancer therapies that offer new treatment avenues for patients. The oncology space continues to be fiercely competitive, with companies striving to deliver more precise and effective cancer treatments. Turning to clinical trials, AstraZeneca's Imfinzi has shown promising results in a phase 3 trial focused on bladder cancer patients who are not eligible for cisplatin-based chemotherapy. These findings position Imfinzi as a strong competitor to Merck's Keytruda and reinforce AstraZeneca's strategic focus on expanding its oncology portfolio through novel combinations and indications. In the realm of genetic therapies, Regenxbio has achieved a milestone with its gene therapy for Duchenne muscular dystrophy. This therapy met its primary endpoint in pivotal trials, highlighting the potential of gene therapies to address rare diseases with limited treatment options. Such successes are likely to encourage further investment in gene editing technologies, which hold significant promise for tackling conditions once deemed untreatable. The FDA is also exploring frameworks to repurpose existing drugs for new uses by leveraging existing safety data. This could streamline drug development processes and offer cost-effective solutions for patients with complex conditions. However, this approach will need rigorous validation of efficacy in new indications to ensure patient safety and therapeutic effectiveness. Despite setbacks in its Alzheimer's research, Biogen remains steadfast in its efforts. While their tau-targeting candidate did not meet primary endpoints in a phase 2 trial, reductions in tau pathology and cognitive benefits were observed. This perseverance showcases Biogen's commitment to finding innovative approaches to tackle Alzheimer's disease despite ongoing challenges. On the operational front, Taiwan's Bora Group is acquiring Macrogenics' CDMO operations for up to $127.5 million. This move reflects a broader trend of consolidation within the CDMO space as companies aim to enhance their production capabilities and streamline operations. Quality control remains a critical concern as evidenced by Sun Pharma's recent recall of a chemotherapy batch due to glass particle contamination. Incidents like these underline the importance of stringent quality assurance measures throughout the manufacturing process to ensure patient safety. Moreover, Viz.ai has launched an AI-powered pulmonary care platform aimed at integrating acute and chronic care workflows. This development signals an increasing adoption of artificial intelligence in healthcare, promising improvements in diagnostics and patient management efficiency. AI continues to gain traction as Isomorphic Labs recently secured $2.1 billion in Series B funding aimed at enhancing AI-driven drug design models. Similarly, Charles River has introduced an AI-powered digital pathology platform poised to Support the show

Gene therapy has been quietly pulling off miracles, and this week, it got its Oscars moment. Emma Varvaloucas, Executive Director of The Progress Network, breaks down how a husband-and-wife scientific team's decades-long quest has restored sight to over 100 blind Americans, and how a brand-new drug called Otarmeni just became the first-ever FDA-approved gene therapy for genetic deafness. The science is extraordinary. The price tags, less so.Plus: The United Kingdom passes a genuinely radical generational ban on smoking; the US Senate unanimously bans members and staffers from betting on prediction markets, after some were caught betting on their own races; and Meta inks a deal to beam solar power down from space.What Could Go Right? is produced by The Progress Network and Kaleidoscope.For transcripts, to join the newsletter, and for more information, visit: theprogressnetwork.orgSubscribe to our (FREE) Substack newsletter: https://theprogressnetwork.org/newsletter/Watch the podcast on YouTube: / theprogressnetworkFollow us on X, Instagram, Facebook, TikTok: @progressntwrkFollow Emma on Instagram: https://www.instagram.com/heyemmavarv/

2020 Llura Liggett Gund Award recipient honored for pioneering gene therapy that transformed vision research

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In a rapidly evolving industry landscape, artificial intelligence has emerged as a game-changer, transforming how major pharmaceutical companies approach drug development and diagnostics. Roche's strategic acquisition of PathAI for over $1 billion exemplifies this shift, highlighting the growing importance of AI-driven diagnostics in digital pathology. This move signals a broader trend where AI is no longer just a theoretical concept but a practical tool enhancing healthcare delivery. Alnylam's recent challenges with its web-based presentation of Amvuttra data underscore the need for accuracy in representing clinical data digitally—showing that while AI can offer innovative ways to present data, it also demands rigorous standards to ensure clarity and prevent misleading claims. On the regulatory front, the FDA's evolving stance on cell therapy Ebvallo, alongside its new one-day assessment pilot program, is shaping the industry's regulatory environment. The reconsideration of Ebvallo's earlier rejection due to single-arm trial data concerns illustrates the FDA's willingness to adapt its regulatory framework to accommodate innovative therapies. This adjustment could potentially pave the way for other gene therapies in development, including those by UniQure. Moreover, Sanofi's withdrawal of Tzield from the FDA's contentious Commissioner's National Priority Voucher program reflects ongoing debates about expedited review processes, underscoring the need for transparent and efficient pathways for bringing new therapies to patients swiftly. Additionally, the FDA's AI-guided inspection pilot aims to modernize compliance strategies and enhance pharmaceutical manufacturing oversight. In clinical trials, companies continue to face both triumphs and setbacks. Entrada Therapeutics experienced a significant decline in stock value following underwhelming Duchenne Muscular Dystrophy trial results, potentially reshaping competitive dynamics in favor of rivals like Novartis. Conversely, Angelini Pharma is making strategic moves with its $4.1 billion acquisition of Catalyst Pharmaceuticals, targeting market expansion in the U.S. through Firdapse, which is poised to make significant impacts in treating rare diseases. MingMed Biotechnology's promising phase 2 results for QA102 could signal new treatment paradigms for dry AMD—a condition with limited current interventions. Therapeutic innovation is also being driven by policy shifts that encourage research into psychedelic drugs for mental health treatment. Optimi Health's IPO indicates growing investor interest in this area, fueled by regulatory easing under recent executive orders aimed at facilitating psychedelic research. Strategic pipeline adjustments are evident as companies realign their focus based on emerging data insights. Ascendis Pharma's decision to halt its IL-2 oncology program marks a shift toward more promising avenues, while Beone Medicines' restructuring reflects a similar strategy by discontinuing several early-stage cancer programs. The industry's dynamism is further illustrated by Eli Lilly's substantial $4.5 billion investment in expanding its Indiana campus. This move not only enhances Lilly's capacity for genetic medicine and metabolic disease manufacturing but also underscores a broader industry commitment to precision medicine and biologics—fields anticipated to play pivotal roles in future healthcare solutions. Meanwhile, Bayer's acquisition of Perfuse Therapeutics seeks to bolster its ophthalmology portfolio, addressing significant unmet needs in eye disease treatments. Novo Nordisk's success with Wegovy highlights strong market demand for effective obesity treatments, demonstrating an industry-wide shift towards addressing lifestyle-related diseases. LegislSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode dives into the ever-evolving landscape of the pharmaceutical and biotechnology industries, which are experiencing significant transformations driven by scientific advancements, strategic realignments, and regulatory changes. Sanofi is making a significant move by investing $294 million to expand its AI center of excellence in Toronto. This investment is part of a broader trend in the sector to optimize pharmaceutical operations and accelerate drug development through digital transformation. By enhancing its AI capabilities, Sanofi aims to streamline processes and reduce time-to-market for new drugs, positioning itself as a leader in this digital era. In clinical trials, Cytokinetics has reported a pivotal success with MyoKardia's drug Myqorzo in a Phase 3 trial aimed at treating non-obstructive hypertrophic cardiomyopathy. If approved, Myqorzo would be the first treatment available for this condition, highlighting ongoing efforts within the industry to address unmet medical needs with innovative therapies. However, not all ventures meet expectations. Pfizer's acquisition of Trillium Therapeutics for $2.3 billion did not materialize as hoped, leading to the discontinuation of its remaining clinical-stage candidates. This outcome underscores the risks inherent in pharmaceutical investments and the importance of thorough evaluation of potential therapeutic candidates. Similarly, Vertex Pharmaceuticals encountered challenges with its inhaled cystic fibrosis candidate developed with Moderna due to tolerability issues, highlighting patient safety's role in clinical trials. Strategic shifts are also taking place in workforce management. BioNTech plans to cut 1,860 jobs as it exits manufacturing sites in Germany and Singapore, reflecting broader industry trends toward operational optimization. Similarly, Novartis is closing its manufacturing site in Wehr, Germany, resulting in 220 job cuts as part of efforts to streamline operations. Regulatory developments continue to shape industry dynamics. Axsome Therapeutics received FDA approval for Auvelity as a treatment for agitation associated with Alzheimer's disease. This not only enhances Axsome's market potential but also underscores the critical role of regulatory agencies in facilitating access to treatments for complex conditions. Moreover, CAR-T therapies are expanding beyond oncology into autoimmune diseases. Kyverna Therapeutics is advancing toward a groundbreaking approval for CAR-T therapy in autoimmune disorders, marking an evolution in therapeutic applications. The recent developments underscore a dynamic phase characterized by technological innovation and strategic restructuring. AI technologies are revolutionizing drug discovery processes while successful clinical trials expand treatment options for previously unmet needs. Yet challenges remain with investment risks and organizational realignments reshaping operational strategies. Pfizer's discontinuation of its investment in Trillium Therapeutics due to inadequate clinical results emphasizes the necessity for robust data to support therapeutic viability. On a regulatory front, Strand Therapeutics stresses reforming the FDA's Investigational New Drug process to maintain U.S. leadership in biomedical innovation amid global competition. Passage Bio's strategic review following regulatory setbacks with its gene therapy program further exemplifies biotechnological unpredictability. Viridian Therapeutics' success with its anti-IGF-1R antibody bodes well for FDA approval and competition against established players like Amgen. The formation of the American Biotech Innovation Alliance signifies efforts to unify domestic biotech strategies amid global competition. Investments continue despite these challenSupport the show

Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Gene therapy approved to restore hereditary hearing loss; investigational treatment shows hair coverage improvements in male pattern loss; Breztri approved as a maintenance treatment for asthma; gene editing candidate meets endpoints in hereditary angioedema trial; novel dual glucagon/GLP-1 receptor agonist demonstrates significant weight loss.

Nicole Johnson and Nasha Fitter are both mothers of daughters with the ultra-rare neurodevelopmental condition FOXG1 syndrome, which currently has no approved disease-modifying therapies. The disorder causes profound developmental disabilities, epilepsy, motor and speech impairments, and multi-system challenges. The two mothers co-founded the FOXG1 Research Foundation to advance treatments for the condtion. Johnson and Fitter discuss how a parent-driven foundation became a virtual biotech capable of advancing a gene therapy into human clinical trials, how they prioritized translational work over academic projects that don't move a therapy toward the clinic, and the lessons they've learned that can guide other rare disease communities.

What is ocular gene therapy, and could it treat inherited retinal diseases like Stargardt and Usher syndrome? In this episode, I'm joined by Dr. Jayashree Sahni of AAVantgarde to break down how gene therapy works, what clinical trials involve, and what patients can expect. We cut through the myths and explore the real potential of gene therapy for vision loss. Contact AAVantgarde to learn more: ► www.aavantgarde.com ► clinicaltrials@aavantgarde.com ► patientadvocacy@aavantgarde.com Get the full transcription here: ► https://docs.google.com/document/d/17yR24WkAZ2lHd1iCoKXtANoZ-vFd6XqU5K5d154kjgE/edit?usp=sharing #GeneTherapy #Stargardts #RetinitisPigmentosa #Blindness #VisionLoss #AssistiveTechnology #ClinicalTrials #EyeHealth #AAVantgarde

CSL Behring just announced a global "stockout" of Hemgenix—what's happening, and what does it mean for patients? On this episode of BloodStream Podcast, we break down the news, launch our mini-series on plasma donation, and hear from Thomas Savage in our I'm Fine segment, sharing the highs, the lows, and the reality of living with a severe bleeding disorder.  Pain, perseverance, and the lessons learned along the way give a rare, unfiltered glimpse into life behind the headlines—reminding us all that every treatment, every donation, and every day matters. Show Notes: I'm Fine is presented by @SanofiUS  #bloodstreammedia #raredisease #bleedingdisorders #podcast #chronicdisease #hemophiliacommunity #advocacy   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more. Subscribe: The BloodStream Podcast   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on X/Twitter  BloodStream on Instagram BloodStream on LinkedIn BloodStream on TikTok  

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Senate Insulin Act moves forward, FDA approveds Awiqli for type 2 and and second oral GLP-1 pill, lots of updates on stem cell and gene therapy for type 1, updates from Beta Bionics, veterans group and Dexcom team up, and Omnipod features on Scrubs. Much more in the episode! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Stacey mentioned these two groups:  Grownup T1Ds T1D to 100 Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com